Corient Private Wealth LLC Has $3.52 Million Holdings in Charles River Laboratories International, Inc. $CRL

Corient Private Wealth LLC boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 68.5% in the fourth quarter, HoldingsChannel reports. The firm owned 17,628 shares of the medical research company’s stock after acquiring an additional 7,166 shares during the period. Corient Private Wealth LLC’s holdings in Charles River Laboratories International were worth $3,516,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in CRL. Tema Etfs LLC bought a new position in Charles River Laboratories International during the fourth quarter worth about $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at about $42,000. Sfam LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at about $43,000. Activest Wealth Management raised its position in shares of Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. raised its position in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 145 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CRL. Morgan Stanley upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $185.00 to $220.00 in a report on Wednesday, June 17th. Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Evercore reissued an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. Finally, CLSA upgraded shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their price objective for the company from $167.00 to $219.00 in a research report on Friday, May 29th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average target price of $211.00.

Charles River Laboratories International Price Performance

Shares of CRL opened at $215.68 on Friday. The stock has a 50 day simple moving average of $176.98 and a 200 day simple moving average of $183.36. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $228.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The firm has a market capitalization of $10.39 billion, a PE ratio of -57.36, a P/E/G ratio of 2.46 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same period last year, the company posted $2.34 EPS. The business’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.